Seridopidine
CAS No. 883631-51-4
Seridopidine( —— )
Catalog No. M34708 CAS No. 883631-51-4
Seridopidine (ACR343) is a modulator of dopaminergic activity that is used as an oral therapy for schizophrenia, Parkinson's disease, and Tourette's syndrome.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 216 | Get Quote |
|
| 5MG | 333 | Get Quote |
|
| 10MG | 504 | Get Quote |
|
| 25MG | 790 | Get Quote |
|
| 50MG | 1086 | Get Quote |
|
| 100MG | 1431 | Get Quote |
|
| 500MG | 2871 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameSeridopidine
-
NoteResearch use only, not for human use.
-
Brief DescriptionSeridopidine (ACR343) is a modulator of dopaminergic activity that is used as an oral therapy for schizophrenia, Parkinson's disease, and Tourette's syndrome.
-
DescriptionSeridopidine (ACR343) is a modulator of dopaminergic activity that is used as an oral therapy for schizophrenia, Parkinson's disease, and Tourette's syndrome.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetDopamine Receptor
-
RecptorDopamine Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number883631-51-4
-
Formula Weight285.38
-
Molecular FormulaC14H20FNO2S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESS(C)(=O)(=O)C=1C=C(C=C(F)C1)C2CCN(CC)CC2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Sertindole
Sertindole is an atypical antipsychotic that binds to dopamine D2 receptors and the serotonin (5-HT) receptor subtypes 5-HT1D 5-HT2A and 5-HT2C (Kds = 2.7 20 0.14 and 6 nM respectively).
-
Chlorpromazine
Chlorpromazine (CPZ) is a phenothiazine acting as dopamine antagonist.Chlorpromazine is a low-potency typical antipsychotic agent for the treatment of psychotic disorders such as schizophrenia.Chlorpromazine (CPZ) is a phenothiazine acting as dopamine antagonist.?
-
Syrosingopine
Syrosingopine has selective depleting effect on brain amines is potentiated by combined treatment with disulfiram or fusaric acid, a dopamine beta-hydroxylase inhibitor.
Cart
sales@molnova.com